News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results For AST-OPC1 5/24/2016
Celsion (CLSN) Announces Presentation Of OVATION Study Clinical Trial Design At Upcoming ASCO 2016 Meeting 5/24/2016
Eli Lilly (LLY) Projects 20 New Product Launches in 10 Years with 20 Possible Expansions 5/24/2016
AmpliPhi Bio (APHB) Announces Start Of First Phage Therapy Trial In U.S. Under IND 5/24/2016
Regulus (RGLS) Appoints Allison Wey As Vice President, Investor Relations & Corporate Communications 5/23/2016
CryoPort To Provide Cold Chain Logistics Support For International Stem Cell Corporation's Phase I Clinical Trial For The Treatment Of Parkinson's Disease 5/23/2016
Rexahn Pharmaceuticals, Inc. (RNN) To Present At The ASCO 2016 Annual Meeting 5/23/2016
Akari Therapeutics Receives Positive Opinion For Orphan Drug Designation For Coversin In The European Union For Treatment Of Guillain Barré Syndrome 5/23/2016
13 Massachusetts Cancer Biotechs Looking to Shake Things Up at ASCO in June 5/20/2016
Merrimack (MACK) And Baxalta (BXLT) Announce Initiation Of Phase 1 Study Of MM-151 In Combination With The ONIVYDE (Irinotecan Liposome Injection) Regimen In Metastatic Colorectal Cancer 5/19/2016
AbbVie (ABBV) Demonstrates Progress In Oncology Research At ASCO 2016 Annual Meeting With Multiple Abstracts Evaluating Eight Medicines Across Cancer Types 5/19/2016
Amgen (AMGN) Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients 5/19/2016
Bayer (BAY) To Showcase Latest Oncology Research At ASCO 2016 5/19/2016
Mirati Therapeutics  (MRTX) To Present Abstracts On Pipeline Programs At 2016 ASCO Annual Meeting 5/19/2016
Regulus (RGLS) To Present At The 2016 UBS Global Healthcare Conference 5/19/2016
Merrimack (MACK) Announces A Leading-Edge Biomarker-Selected, Multi-Arm Basket Trial That Matches Patients With Most Appropriate Combination Regimens 5/19/2016
Spark Therapeutics (ONCE), Pfizer (PFE)'s Hemophilia B Gene Therapy Candidate Shows Promise in Early Studies 5/19/2016
Astellas Oncology Announces Data To Be Presented At 2016 ASCO Annual Meeting 5/19/2016
MabVax Therapeutics' Antibody Discovery Platform And Humab-5B1 Cancer Therapeutic Featured In Presentation At America's Antibody Congress 5/19/2016
Infinity Pharmaceuticals Inc. (INFI) Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming European Hematology Association And ASCO Meetings 5/19/2016
Concert Pharmaceuticals, Inc. (CNCE) Initiates Phase 1 Trial Of CTP-543 As A New Treatment For Alopecia Areata 5/19/2016
PharmaMar Reports Positive Results From The Phase I Study Of Plitidepsin In Combination With Bortezomib And Dexamethasone In Patients With Multiple Myeloma At The 2016 ASCO Annual Meeting 5/19/2016
Cerulean Pharma Inc. (CERU) To Present At The 2016 ASCO Annual Meeting 5/19/2016
Celgene (CELG) Announces Presentations Of Investigational Studies In Solid Tumor And Blood Cancers At ASCO 2016 5/19/2016
Nordic Nanovector First Quarter 2016 Results: Strong Progress On All Priorities And Execution On Track 5/19/2016
Cerulean Pharma Inc. (CERU) Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference 5/19/2016
Initial Efficacy Data For GlycoMimetics, Inc. (GLYC)’ GMI-1271 Combined With Chemotherapy In Patients With AML To Be Presented At European Hematology Association 21st Congress 5/19/2016
PharmaMar Announces New Data On Yondelis, Plitidepsin And PM1183 To Be Presented At 2016 ASCO Annual Meeting 5/19/2016
Oncoceutics Release: ONC201 Clinical Trial Results Accepted For 2016 ASCO Poster Discussion 5/19/2016
Novartis Pharmaceutical Corporation (NVS) To Present Pivotal Data In Hematologic And Solid Tumor Cancers At 2016 ASCO Annual Meeting 5/19/2016
True North Therapeutics To Present Clinical Data In Patients With Cold Agglutinin Disease (CAD) For Lead Product Candidate TNT009 5/19/2016
Merck & Co. (MRK) and Pfizer (PFE) Collaboration Working as Combo Drug Bears Fruit in Small Study 5/19/2016
Breadth And Depth Of Bristol-Myers Squibb (BMY)’s Immuno-Oncology Clinical Development Program To Be Showcased At 2016 ASCO Annual Meeting 5/18/2016
Synthon Advances Clinical Evaluation Of Anti-HER2 ADC SYD985 In An Expanded Cohort Of HER2-Positive Metastatic Breast Cancer Patients 5/18/2016
Asterias Biotherapeutics Reports First Quarter Results 5/17/2016
Protagonist Therapeutics To Present New Data For PTG-100 And PTG-200 At Digestive Disease Week 2016 5/17/2016
BioSight Release: Arkin Holdings And Primera Capital Lead An Investment Of $13M In Biosight For An Innovative Treatment Of Acute Leukemia 5/16/2016
BioLineRx And MaRS Innovation Sign Framework Collaboration Agreement 5/16/2016
Dermata Therapeutics, LLC Announces Initiation Of Phase 1 Pharmacokinetic Study 5/16/2016
MabVax Therapeutics' HuMab-5B1 Cancer Therapeutic Featured In Presentation At AACR Special Meeting On Pancreatic Cancer 5/16/2016
Upsher-Smith Laboratories Announces Start Of First In Human Clinical Trial In Oncology With Novel CXCR4 Antagonist USL311 5/16/2016
Celsion (CLSN) Reports First Quarter 2016 Financial Results And Provides Business Update 5/16/2016
Regeneus (RGS.AX) Enrollment Complete And Positive Safety In Progenza Trial For Osteoarthritis 5/16/2016
Seres Therapeutics Reports First Quarter Financial Results And Provides Operational Progress Update 5/16/2016
Merck & Co. (MRK) Release: New KEYTRUDA (Pembrolizumab) Data At 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data In Melanoma And Updated Overall Survival Data In Non-Small Cell Lung Cancer As Well As Updated Findings In Head And Neck Cancer 5/16/2016
Dermata Therapeutics Announces Initiation Of Phase 1 Pharmacokinetic Study 5/16/2016
Capricor Therapeutics, Inc. Provides Corporate Update And Reports First Quarter 2016 Financial Results 5/13/2016
Tobira Announces Publication Of Phase 1 Study Results Showing Cenicriviroc Safety In Cirrhotic Patients 5/13/2016
AmpliPhi Bio (APHB) Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/13/2016
Asterias Biotherapeutics Announces Closing Of Public Offering Of Common Stock And Warrants, And Exercise Of Over-Allotment Option To Purchase Additional Warrants 5/13/2016
NeuralStem Inc. To Raise $1.08 Million 5/13/2016
Dicerna (DRNA) Announces Dosing Of First Patient In Phase 1 Clinical Trial Of DCR-PH1 In Patients With Primary Hyperoxaluria Type 1 (PH1) 5/13/2016
Sensorion To Present Data From Phase Ib Clinical Trial Of SENS-111 At AAO-HNSF Annual Meeting 5/12/2016
Mologen AG (MOLGF.PK): Further Progress In Clinical Studies With Lead Product Lefitolimod In Q1 2016 5/12/2016
aTyr Pharma Announces First Quarter 2016 Operating Results 5/12/2016
RXi Pharma (RXII) Reports First Quarter 2016 Financial Results And Highlights Recent Corporate Developments 5/12/2016
ProtoKinetix Inc. (PKTX.OB) Updates Progress Toward Clinical Trial Application For AAGP 5/12/2016
Viking Therapeutics (VKTX) Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/11/2016
Intrexon (XON) Announces First Quarter 2016 Financial Results 5/11/2016
Arrowhead Pharma (ARWR) Reports Fiscal 2016 Second Quarter Results 5/11/2016
BioTime (BTX) Reports First Quarter Results And Recent Corporate Accomplishments 5/11/2016
H3 Biomedicine Receives FDA Acceptance For Investigational New Drug Application 5/11/2016
Blueprint Medicines (BPMC) Reports First Quarter 2016 Financial Results 5/10/2016
Abide Therapeutics Announces First Subject Dosed In PET Occupancy Study with [18F]ABX-1488, A Proprietary Human Monoacylglycerol Lipase (MGLL)-Specific PET Ligand 5/10/2016
Arena (ARNA) Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/10/2016
Galapagos (GLPG.BR) Starts Phase 1 Study With Potentiator GLPG2451 For CF 5/10/2016
AM-Pharma Publishes Safety And Pharmacokinetic Data From Phase I recAP Trial 5/10/2016
BIND Therapeutics (BIND) Release: Data Published In Journal Of Controlled Release Demonstrate Flexibility Of ACCURINS To Encapsulate A Broad Range Of Physically And Chemically Diverse Payloads With High Encapsulation Efficiency And Tunable Release Kinetics 5/10/2016
Araim Pharmaeuticals Release: Queen's University Belfast To Study The Innate Repair Activator ARA 290 In Diabetic Macular Edema 5/10/2016
Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal Second Quarter Ended March 31, 2016 5/10/2016
Dicerna (DRNA) Reports First Quarter 2016 Financial and Operational Results 5/10/2016
Verastem (VSTM) Reports First Quarter 2016 Financial Results 5/10/2016
Bellicum (BLCM) Reports First Quarter 2016 Financial Results 5/10/2016
Opko Health (OPK) Reports First Quarter Financial And Operating Results 5/10/2016
X4 Pharma Announces Initiation Of Phase 1/2 Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma 5/9/2016
Avelas Biosciences Announces Positive Interim Phase 1b Results And Advances To Dose Expansion Stage 5/9/2016
Sangamo (SGMO) Presents Recent Developments From Research And ZFP Therapeutic Programs In Multiple Presentations At Annual Meeting Of The American Society Of Gene And Cell Therapy 5/9/2016
MGB Biopharma Limited's Pre-IND Meeting With FDA Provides Clear Guidelines On Further Development Of Oral MGB-BP-3, A Truly Novel Antibiotic Targeting Clostridium Difficile Infections 5/9/2016
Dimension Therapeutics Announces Preclinical Data From Bayer-Partnered Hemophilia A Program At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting 5/9/2016
Kamada Ltd. (KMDA) Reports 2016 First Quarter Financial Results 5/9/2016
BIND Therapeutics (BIND) Reports First Quarter 2016 Financial Results And Provides Business Update 5/9/2016
Incyte (INCY) Reports 2016 First-Quarter Financial Results And Updates Shareholders On Key Clinical Programs 5/9/2016
Seres Therapeutics To Host First Quarter 2016 Financial Results And Operational Progress Conference Call And Webcast On May 16, 2016 5/9/2016
bluebird bio (BLUE) Presents Oncology And Gene Therapy Data At The ASGCT 19th Annual Meeting 5/9/2016
TopiVert To Present First In Human Data From Its Phase I Clinical Study With TOP1288 At DDW 2016 In San Diego 5/9/2016
NeuralStem Inc. Reports Fiscal First Quarter 2016 Results And Business Update 5/9/2016
DURECT (DRRX) Announces First Quarter 2016 Financial Results And Update Of Programs 5/6/2016
Oncolytics Biotech Inc. (ONC.TO) Announces 2016 First Quarter Results 5/6/2016
Concert Pharmaceuticals, Inc. (CNCE) Unveils CTP-543 For Treatment Of Alopecia Areata 5/5/2016
aTyr Pharma Appoints Grove Matsuoka As Senior Vice President, Product Programs And Planning 5/5/2016
Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports First Quarter 2016 Financial Results 5/5/2016
Encore Vision Announces Successful Phase I-II Study Of Topical EV06 For The Treatment Of Presbyopia 5/5/2016
bluebird bio (BLUE) Reports First Quarter 2016 Financial Results And Recent Operational Progress 5/5/2016
Juniper Pharma (JNP) Announces Publication Of Phase 1 Study Demonstrating Ability Of Its Proprietary Intravaginal Ring To Deliver Large Molecules 5/5/2016
Merus Announces First Patient Dosed In Phase I/II Trial Evaluating Bispecific Antibody Candidate MCLA-117 In Patients With AML 5/4/2016
RXi Pharma (RXII) To Present An Update On Its Consumer Health Programs At The Society For Investigative Dermatology 75th Annual Meeting 5/4/2016
GlycoMimetics, Inc. (GLYC) Reports First Quarter 2016 Results 5/4/2016
Isarna Therapeutics Presents First Interim Phase I Data For ISTH0036 In Advanced Glaucoma At Association for Research in Vision & Ophthalmology 2016 Annual Conference 5/4/2016
Affibody Announces Initial Results From Phase I Psoriasis Study Of ABY-035 5/4/2016
Xencor Reports First Quarter 2016 Financial Results 5/3/2016
NeuralStem Inc. Announces Proposed Public Offering Of Securities 5/3/2016
RXi Pharma (RXII) And Thera Neuropharma Enter Into An Exclusive License Agreement For RXi's Self-Delivering RNAi (sd-rxRNA) Platform Targeting SOD1 To Develop Therapeutics For Neurodegenerative Diseases, Such As ALS (Lou Gehrig's Disease) 5/3/2016
Regen BioPharma Receives Preliminary Clinical Data From Pan Am Cancer Center Regarding Their HemaXellerate Study In Cancer Patients 5/3/2016
Sangamo (SGMO) Reports First Quarter 2016 Financial Results 5/3/2016
Corium International, Inc. Announces Streamlined Bioequivalence Development Path For Transdermal Corplex Donepezil Following Positive Pre-IND Communication From FDA 5/3/2016
NW Bio (NWBO) Announces Operations Updates 5/3/2016
Cerulean Pharma Inc. (CERU) Reports First Quarter 2016 Corporate Highlights And Financial Results 5/3/2016
Genentech (RHHBY) Highlights Personalized Medicines And Cancer Immunotherapies At 2016 ASCO Annual Meeting 5/3/2016
Regeneron (REGN)'s Pain Drug Fasinumab Meets Goals in Late Stage Study 5/2/2016
SELLAS Life Sciences Group Announces Initiation Of Galinpepimut-S (WT1 Cancer Vaccine) Phase 1 Clinical Trial In Combination With PD-1 Checkpoint Inhibitor For Patients With Ovarian Cancer 5/2/2016
Celsion (CLSN) Announces Positive Data From The First Cohort Of Patients In The OVATION Study 5/2/2016
Novogen Limited (NVGN) Provides Update On Development Of Cantrixil 5/2/2016
Protalex, Inc. (PRTX) Receives Positive Interim Review From Independent Safety Monitoring Committee In Its European Phase Ib Study Of PRTX-100 To Treat Immune Thrombocytopenia 5/2/2016
GenVec (GNVC) Provides Update On Hearing Loss Clinical Program 5/2/2016
Encore Vision Announces Positive Results From The Phase I-II Study Of Topical EV06 For The Treatment Of Presbyopia 5/2/2016
Concert Pharmaceuticals, Inc. (CNCE) Announces Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-656, Lead Candidate For The Treatment Of Cystic Fibrosis 4/29/2016
ImmunoGen (IMGN) Reports Third Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update 4/29/2016
Corcept Therapeutics Inc. (CORT) Release: Promising Pre-Clinical And Phase 1 Data Support Advance Of Selective Cortisol Modulator CORT125134 As Potential Treatment For Cushing's Syndrome And Solid-Tumor Cancers 4/29/2016
Cytuvax Reports Interim Results Of The Phase I Clinical Trial With The HBAI20 Hepatitis B Vaccine For Non-Responders 4/29/2016
DURECT (DRRX) Announces Closing Of Public Offering Of Common Stock 4/29/2016
Seattle Genetics (SGEN) Reports First Quarter 2016 Financial Results 4/29/2016
IBC Generium Selects Goodwin Biotechnology, Inc. To Optimize The Process, Scale-Up, And Manufacture An Igg-Based Bispecific Antibody For Phase I Clinical Trials 4/28/2016
Regen BioPharma 's HemaXellerate Therapy For Treating Aplastic Anemia Licensed For Proof Of Concept Study 4/28/2016
RXi Pharma (RXII) Announces Advancement Of Its Ophthalmology Franchise With Successful Topical Delivery Of sd-rxRNA To The Cornea In An In Vivo Corneal Wound Model 4/28/2016
Celgene (CELG) Reports First Quarter 2016 Operating And Financial Results 4/28/2016
Agenus (AGEN) Reports First Quarter 2016 Financial Results And Operational Progress 4/28/2016
Alkermes (ALKS) Announces Plan To Initiate Second Clinical Trial Of ALKS 7119 Based On Preliminary Phase 1 Results 4/28/2016
Agenus (AGEN) Commences Phase I Clinical Trial Of Its CTLA-4 Checkpoint Antibody To Treat Solid Tumors 4/27/2016
From 20 to 84 Employees in Just Four Years, Booming Blueprint Medicines (BPMC) Maps Out a Plan 4/26/2016
Exicure Announces Dosing Of First Patient In Phase I Trial For The Treatment Of Chronic Plaque Psoriasis 4/26/2016
ProtoKinetix Inc. (PKTX.OB) Outlines Steps To Clinical Trial Application For AAGP 4/26/2016
Asterias Biotherapeutics To Present At Stem Cell Summit 2016 4/26/2016
Queen’s University Belfast And Domainex Ltd Win Late-Stage Award To Progress Novel Lung Cancer Drug Candidate Into The Clinic 4/26/2016
Juno (JUNO), Five Prime (FPRX) are Quiet Winners at AACR 4/25/2016
Fibrocell Science, Inc. Receives Orphan Drug Designation From The FDA For FCX-013 For The Treatment Of Localized Scleroderma 4/25/2016
Allovate Announces Positive Results Of Proof-Of-Concept Study Of Oral Mucosal Immunotherapy (OMIT) 4/25/2016
Protalex, Inc. (PRTX) Announces Preliminary Findings From Phase I/II Continuation Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 4/25/2016
Opthea Phase 1 Wet AMD Clinical Trial With OPT-302 Meets Primary Safety Objective 4/25/2016
Cerulean Pharma Inc. (CERU) Announces Oral Presentation Of CRLX101 Clinical Data At Gynecologic Oncology 2016 Conference 4/25/2016
Biogen (BIIB) R&D Spending Dropped 19% from Last Quarter 4/22/2016
NeuralStem Inc. Receives NASDAQ Notice Of Bid Price Deficiency 4/22/2016
Viveve Announces Positive Topline Results For VIVEVE I Clinical Trial 4/22/2016
DelMar Pharma Release: FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer 4/21/2016
ARMO BioSciences Announces AM0010 Clinical Data To Be Presented At The ASCO Annual Meeting In June 2016 4/21/2016
Inotek Pharmaceuticals Corporation (ITEK) Announces Publication Of Phase 1 Data For Trabodenoson In Healthy Adult Volunteers In The Journal OfOcular Pharmacology And Therapeutics 4/21/2016
Juno (JUNO) Unveils Promising Early Data on Two CAR T Cell Product Candidates 4/21/2016
Checkmate Appoints David Mauro, M.D., Ph.D., As Chief Medical Officer And Announces Dosing Of First Patient In Immuno-Oncology Phase 1b Trial With CMP-001, A TLR9 Agonist 4/20/2016
Merck & Co. (MRK) Statement On Blueprint Project Findings Presented At The AACR 2016 Annual Meeting 4/20/2016
iCardiac Technologies Implements New Quality Metric To Enhance Reliability Of Phase I QT Assessment 4/20/2016
vTv Therapeutics Presents Data On Two Diabetes Candidates At Keystone Symposia On New Therapeutics For Diabetes And Obesity 4/20/2016
AmpliPhi Bio (APHB) Provides Update On Phase I Trial: Phage Therapy Well Tolerated In First Cohort 4/20/2016
Xcovery Presents Data Supporting The Potential Efficacy Of X-396 In Patients With ALK+ Non-Small Cell Lung Cancer At The AACR Annual Meeting 2016 4/20/2016
N&N Pharmaceuticals Inc. Commences Clinical Trials On Its Novel Antiviral Drug 4/20/2016
CytRx (CYTR) To Present Updated Aldoxorubicin Clinical Trial Data At The ASCO Annual Meeting In June 2016 4/20/2016
Deciphera’s Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, Demonstrates Potent Macrophage Checkpoint Inhibition As A Single Agent And In Combination With An Anti-PD1 Inhibitor 4/20/2016
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Announces New Clinical Data from First-in-Human Study of ME-401, A Next Generation Oral PI3K Delta Inhibitor 4/20/2016
Celsion (CLSN) Presents Compelling Data At AACR 2016 Demonstrating Synergistic Anti-Cancer Effect Of GEN-1 IL-12 Immunotherapy Plus Avastin And Doxil 4/19/2016
Lycera Announces Progress In Immuno-Oncology Program Presented At The 2016 AACR Annual Meeting 4/19/2016
BeiGene Presents Positive Interim Data From Trial Of RAF-Inhibitor 4/19/2016
DelMar Pharma Updates Ongoing Phase I/II Refractory GBM Clinical Trial With VAL-083 At AACR Annual Meeting 4/19/2016
Bay Area’s GigaGen Develops Synthetic Immune System to Harness Antibodies 4/19/2016
ContraVir Doses First Subject In Phase 1b Clinical Study Of CMX157 For Treating Chronic Hepatitis B Infection 4/19/2016
RXi Pharma (RXII) Fortifies Its Novel RNAi Patent Portfolio With Notice Of Allowance For Lead Clinical Candidate RXI-109 4/19/2016
Lpath (LPTN) Reports Favorable Results From Phase 1 Study Of Lpathomab 4/19/2016
BioLineRx Announces Presentation Of Detailed Mechanism Of Action Data For Lead Oncology Platform At AACR 2016 4/19/2016
Sangamo (SGMO) Announces Presentations On ZFP Therapeutic Programs And Applications At 2016 Annual Meeting Of The American Society Of Gene & Cell Therapy 4/19/2016
EBOVAC1 Release: Global Public-Private Partnership Announces Publication Of Positive Phase 1 Data For Ebola Vaccine Regimen In JAMA 4/19/2016
Intensity Therapeutics, Inc. Reports That INT230-6’s Anti-Cancer Mechanism Is A Combination Of Cell Death With Immune System Activation 4/19/2016
BioSight Completed Treatment Of Patients In Astarabine Phase I/IIa Clinical Trial 4/19/2016
Kite Pharma (KITE) Cancer Therapy Responses in Solid Tumors Continued in Small Trial, NCI Review Halts Patient Enrollment 4/18/2016
FDA Designates Merck & Co. (MRK)'s Keytruda a Breakthrough for Classical Hodgkin Lymphoma 4/18/2016
MabVax Therapeutics' Fully Human Antibody Approach To Cancer Therapeutics And Imaging Featured In Three Presentations At AACR Annual Meeting In New Orleans 4/18/2016
Nektar Therapeutics (NKTR) Release: Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration 4/18/2016
Oncolytics Biotech Inc. (ONC.TO) Collaborators Present REOLYSIN Preclinical Research At The 2016 AACR Annual Meeting 4/18/2016
Fibrocell Science, Inc. And Intrexon Announce Allowance To Commence Phase I/II Trial For FCX-007 For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 4/18/2016
Cyclacel Pharmaceuticals, Inc. (CYCC)’s Second-Generation CDK2/9 Inhibitor, CYC065, Is An Effective Inducer Of Cell Death In B-Cell Lymphoma And Synergizes With Bcl-2 Or BET Inhibitors 4/18/2016
Incyte (INCY) Investor Event At AACR 2016 To Highlight Innovative And Diversified Research And Development Portfolio 4/18/2016
SAGE Therapeutics (SAGE) Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy of Neurology Annual Meeting 4/18/2016
ImmunoGen (IMGN) Announces Initiation Of Clinical Testing Of First-in-Class IMGN779 For Acute Myeloid Leukemia 4/18/2016
Ignyta (RXDX) Announces Updated Data From Entrectinib Phase 1 Clinical Trials At The 2016 AACR Annual Meeting 4/18/2016
Endece To Present Data On NDC-1308, A Small Molecule With Remyelinating Activity For Treatment Of Secondary Progressive Multiple Sclerosis 4/18/2016
Merus To Present Interim Clinical Data From Ongoing Phase I/II Clinical Trial Of Its Lead Bispecific Antibody Candidate, MCLA-128, At The AACR 2016 Annual Meeting 4/18/2016
Loxo Oncology (LOXO) TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers In AACR Phase 1 Update 4/18/2016
Debiopharm Announces Presentation At AACR Of Non-Clinical Data Relating To Its Targeted Investigational Compound Debio 1347/CH5183284, A Selective FGFR 1,2,3 Inhibitor 4/15/2016
Sarah Cannon Research Institute To Present Cancer Research Insights At 2016 AACR Annual Meeting 4/15/2016
Marinus Pharmaceuticals (MRNS) Receives FDA Orphan Drug Designation For Ganaxolone IV To Treat Status Epilepticus 4/15/2016
MabVax Therapeutics Hires Paul Resnick, M.D. As Chief Business Officer 4/15/2016
Tunitas Therapeutics Expands Board Of Directors With Appointment Of Dr. Mervyn Turner 4/14/2016
Juno (JUNO) Announces Data Presentations At The AACR Annual Meeting 4/14/2016
DS Biopharma Presents Late-Breaking News Abstract On DS102 At The European Association For The Study Of The Liver (EASL) International Liver Congress; "DS102: A Bioactive Lipid For The Treatment Of NASH" 4/14/2016
Booming Seres Therapeutics Looks to Move Lead Product into Phase III, Expand in Cambridge 4/14/2016
Noveome Debuts with Top-Line Data from Three Phase I Clinical Trials 4/13/2016
DURECT (DRRX) Announces FDA Acceptance Of REMOXY NDA, PDUFA Date Of September 25, 2016 4/13/2016
PDS Biotechnology Corporation Reports Positive Phase 1 Study Results For PDS0101 Immunotherapy For HPV-Related Cancers 4/13/2016
Oncternal Therapeutics Awarded Exclusive Worldwide License To ROR1 Antibody And Related Programs From University of California, San Diego (UCSD) 4/13/2016
Apexigen To Present Data On Its Novel Immuno-Oncology Program APX005M At Upcoming Cancer Conferences 4/13/2016
Proteon (PRTO) Announces Publication In The Journal Of Cardiovascular Pharmacology Of Promising Nonclinical Results For Vonapanitase In Peripheral Artery Disease 4/13/2016
AmpliPhi Biosciences Corporation (APHB) Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients 4/13/2016
Karos Pharmaceuticals Advances Development Of KAR5585 To Treat Pulmonary Arterial Hypertension Into The Clinic 4/13/2016
107th Annual Meeting Of AACR: Bayer (BAY) To Present New Data On Advancing Oncology Portfolio 4/13/2016



//-->